Notable Labs

Notable Labs P/CF

P/CF (Price-to-Cash-Flow Ratio) of Notable Labs (NTBLQ) as of Nov 11, 2026.

P/CF

-0.00

YoY

130.31%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Notable Labs is 2023 -0.00 . P/CF (Price-to-Cash-Flow Ratio) of Notable Labs was 2022 -0.00 . It decreases by 130.31% lower compared to the previous year.

The Notable Labs P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2016
-0.00 USD
Jan 1, 2017
-0.00 USD
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
-0.00 USD
The Notable Labs P/CF history
YEARP/CFYoY
-0.00+130.31%
-0.00-20.92%
-0.00-6.41%
-0.00-44.01%
-0.00+19.79%
-0.00-75.64%
-0.00+251.05%
-0.00-1.57%
-0.00+3.79%
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Notable Labs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Notable Labs

All Key Metrics — Notable Labs